Background
Surgery is considered to be a potentially curative approach for gastric cancer. However, most cases are diagnosed at a very advanced stage for the lack of typical symptoms in the initial stage, which makes it difficult to completely surgical resect of tumors. Early diagnosis and precise personalized intervention are urgent issues to be solved for improving the prognosis of gastric cancer. Herein, we developed an RGD-modified ROS-responsive multifunctional nanosystem for near-infrared (NIR) imaging and photothermal therapy (PTT) against gastric cancer.
Methods
Firstly, the amphiphilic polymer was synthesized by bromination reaction and nucleophilic substitution reaction of carboxymethyl chitosan (CMCh) and 4-hydroxymethyl-pinacol phenylborate (BAPE). Then, it was used to encapsulate indocyanine green (ICG) and modified with RGD to form a smart multifunctional nanoparticle targeted to gastric cancer (CMCh-BAPE-RGD@ICG). The characteristics were determined, and the targeting capacity and biosafety were evaluated both in vitro and in vivo. Furthermore, CMCh-BAPE-RGD@ICG mediated photothermal therapy (PTT) effect was studied using gastric cancer cells (SGC7901) and SGC7901 tumor model.
Results
The nanoparticle exhibited suitable size (≈ 120 nm), improved aqueous stability, ROS-responsive drug release, excellent photothermal conversion efficiency, enhanced cellular uptake, and targeting capacity to tumors. Remarkably, in vivo studies suggested that CMCh-BAPE-RGD@ICG could accurately illustrate the location and margin of the SGC7901 tumor through NIR imaging in comparison with non-targeted nanoparticles. Moreover, the antitumor activity of CMCh-BAPE-RGD@ICG-mediated PTT could effectively suppress tumor growth by inducing necrosis and apoptosis in cancer cells. Additionally, CMCh-BAPE-RGD@ICG demonstrated excellent biosafety both in vitro and in vivo.
Conclusion
Overall, our study provides a biocompatible theranostic nanoparticle with enhanced tumor-targeting ability and accumulation to realize NIR image-guided PTT in gastric cancer.
Intrauterine adhesion
(IUA) is a common and prevailing complication
after uterine surgery, which can lead to clinical symptoms such as
a low menstrual volume, amenorrhea, periodic lower abdominal pain,
infertility, and so on. Placing a three-dimensional printing hydrogel
between the injured site and the adjacent tissue is considered to
be a physical barrier to prevent adhesion, which can isolate the damaged
area during the healing process. In this work, a tissue hydrogel with
various proportions of a methacrylated gelatin (GelMA) and methacrylated
collagen (ColMA) composite hydrogel loaded with amniotic mesenchymal
stem cells (AMSCs) was constructed by using three-dimensional biological
printing technology. Compared with the single GelMA hydrogel, the
composite antiadhesion hydrogel (GelMA/ColMA) showed an appropriate
swelling ratio, enhanced mechanical properties, and impressive stability.
Meanwhile, the microstructure of the GelMA/ColMA composite hydrogel
showed a denser and interconnected microporous structure. In addition,
the cytotoxicity study indicated that the GelMA/ColMA hydrogel has
a cytocompatibility nature toward AMSCs. Finally, the fabrication
of stem cell encapsulation hydrogels was studied, and the cells could
be released continuously for more than 7 days with the normal cell
function. The results of in vivo experiments indicated that the GelMA/ColMA/hAMSC
(human amnion mesenchymal stem cell) hydrogel can prevent cavity adhesion
in a rat IUA model. Therefore, bioprinting a biodegradable hydrogel
cross-linked by blue light has satisfactory anticavity adhesion effects
with excellent physical properties and biocompatibility, which could
be used as a preventive barrier for intrauterine adhesion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.